[
  {
    "ts": null,
    "headline": "Novo Nordisk A/S (NVO): “Canada’s A Backdoor,” Says Jim Cramer",
    "summary": "We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that was one of the earliest movers in the weight loss drug market. The shares have lost 21% […]",
    "url": "https://finnhub.io/api/news?id=cdce5107db73a468c7cc5b5bde1a49876487cb477f5ff28428d5379577c332da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752345202,
      "headline": "Novo Nordisk A/S (NVO): “Canada’s A Backdoor,” Says Jim Cramer",
      "id": 135902429,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that was one of the earliest movers in the weight loss drug market. The shares have lost 21% […]",
      "url": "https://finnhub.io/api/news?id=cdce5107db73a468c7cc5b5bde1a49876487cb477f5ff28428d5379577c332da"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): I Would “Love” If Trump Praised The Company, Says Jim Cramer",
    "summary": "We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer’s morning show. Over the course of this year, the CNBC […]",
    "url": "https://finnhub.io/api/news?id=b37d97ff9d97e7bd4135b81a6d6391cc24380a9ac90990120bf5034d2b409ecd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752345181,
      "headline": "Eli Lilly and Company (LLY): I Would “Love” If Trump Praised The Company, Says Jim Cramer",
      "id": 135911256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer’s morning show. Over the course of this year, the CNBC […]",
      "url": "https://finnhub.io/api/news?id=b37d97ff9d97e7bd4135b81a6d6391cc24380a9ac90990120bf5034d2b409ecd"
    }
  },
  {
    "ts": null,
    "headline": "FDA willing to trade faster drug reviews for lower prices, Bloomberg reports",
    "summary": "FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the U.S. and other countries, Bloomberg’s Rachel Cohrs Zhang and Sam Hornblower report. Makary said in an interview on Bloomberg Television’s Wall Street Week with David Westin that companies that promise to equalize prices can receive a “national priority review voucher,” which would cut review times to one to two months. The vouchers are part",
    "url": "https://finnhub.io/api/news?id=39b4cc4c3158480c55ef9d63519eb50223d32ca48c2b944773b35b04bc2e6f03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752327363,
      "headline": "FDA willing to trade faster drug reviews for lower prices, Bloomberg reports",
      "id": 135899323,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the U.S. and other countries, Bloomberg’s Rachel Cohrs Zhang and Sam Hornblower report. Makary said in an interview on Bloomberg Television’s Wall Street Week with David Westin that companies that promise to equalize prices can receive a “national priority review voucher,” which would cut review times to one to two months. The vouchers are part",
      "url": "https://finnhub.io/api/news?id=39b4cc4c3158480c55ef9d63519eb50223d32ca48c2b944773b35b04bc2e6f03"
    }
  }
]